Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Zuguang Xia, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Ye Guo, Xiaonan Hong, Junning Cao, MD

Blood (2018) 132 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2018-99-118872

Published: 2018

Journal Articles

Selectively Targeting Checkpoint Kinase By Prexasertib Had Potent Anti-Tumor Activity As Single Agent or Combined with Other Chemotherapeutic Drugs in Diffuse Large B-Cell Lymphoma, Especially Double Hit Lymphoma

Juan Gu, MD PhD, Dennis C Gaughan, Simran Gill, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2018-99-110282

Published: 2018

Journal Articles

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy

Juan Gu, MD PhD, Lianjuan Yang, MD PhD, Dennis C Gaughan, Ling He, MD PhD, Weina Shen, MD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5378.

https://doi.org/10.1182/blood-2018-99-113997

Published: 2018

Journal Articles

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Sumera Khan, MSc, MD, Kyle Runckel, BS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2018-99-118480

Published: 2018

Journal Articles

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Thomas Ippolito, MSc, Cory Mavis, BSc, MSc, Juan Gu, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2018) 132 (Supplement 1): 2951.

https://doi.org/10.1182/blood-2018-99-119048

Published: 2018

Journal Articles

Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models

Shalin K. Kothari, MD, Cory Mavis, BSc, MSc, Juan Gu, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2018-99-116510

Published: 2018

Journal Articles

Repurposing Itraconazole As an Anti-Cancer Agent Against Diffuse Large B-Cell Lymphoma

Juan Gu, MD PhD, Lianjuan Yang, MD PhD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 5195.

https://doi.org/10.1182/blood.V130.Suppl_1.5195.5195

Published: 2017

Journal Articles

Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Junning Cao, Xiaonan Hong, Ye Guo

Blood (2017) 130 (Supplement 1): 2839.

https://doi.org/10.1182/blood.V130.Suppl_1.2839.2839

Published: 2017

Journal Articles

XIAP Knockdown Can Increase the Activity of Caspase 3 and 7, and Restore the Apoptotic Response in Cell Line Models of Rituximab Relapse/Refractory B-Cell Lymphoma

Kyle Runckel, BS, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 1478.

https://doi.org/10.1182/blood.V130.Suppl_1.1478.1478

Published: 2017

Journal Articles

Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models

Shalin Kothari, MD, Juan Gu, MD PhD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 1538.

https://doi.org/10.1182/blood.V130.Suppl_1.1538.1538

Published: 2017

Journal Articles

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

Cory Mavis, BSc, MSc, Pallawi Torka, MD, Alison Zeccola, Priyank P. Patel, MD, Juan Gu, MD PhD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 1542.

https://doi.org/10.1182/blood.V130.Suppl_1.1542.1542

Published: 2017

Journal Articles

PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Maria Bhatti, MD, Thomas Ippolito, MS, Cory Mavis, BSc, MSc, Matthew J. Barth, MD

Blood (2015) 126 (23): 1558.

https://doi.org/10.1182/blood.V126.23.1558.1558

Published: 2015

Journal Articles

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan S Lim, MD PhD, Aradhana Tiwari, Mitchell S. Cairo, MD, Rodney R. Miles, MD PhD, Matthew J. Barth, MD

Blood (2014) 124 (21): 1769.

https://doi.org/10.1182/blood.V124.21.1769.1769

Published: 2014

Journal Articles

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Natalie M. Czuczman, BSc, Sarah Frys, BSc, Pavel Klener, Jr., MD, PhD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 647.

https://doi.org/10.1182/blood.V122.21.647.647

Published: 2013

Journal Articles

MLN4924 An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE) Is Active In Pre-Clinical Models Of Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma

Sarah Belliotti, B.A., Juan Gu, PhD, Cory Mavis, BSc, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2013) 122 (21): 4409.

https://doi.org/10.1182/blood.V122.21.4409.4409

Published: 2013

Journal Articles

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

Juan Gu, PhD, Vivek Yanamadala, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 4413.

https://doi.org/10.1182/blood.V122.21.4413.4413

Published: 2013

Journal Articles

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Andrew Skomra, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan Lim, MD, PhD, Aradhana Awasthi, Ph.D, Mitchell S. Cairo, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2013) 122 (21): 5144.

https://doi.org/10.1182/blood.V122.21.5144.5144

Published: 2013

Journal Articles

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

Cory Mavis, BSc, MSc, Juan Gu, PhD, Joseph Skitzki, MD, Francisco Hernandez, MD, Myron S. Czuczman, MD

Blood (2013) 122 (21): 1828.

https://doi.org/10.1182/blood.V122.21.1828.1828

Published: 2013

Journal Articles

CBL-C137, a Curaxin and Potent Suppressor Of NF-Kb Activity and Modulator Of p53 Function Is Active In Rituximab-Sensitive Or Resistant Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Christopher N. Ibabao, Cory Mavis, BSc, MSc, Jenny Gu, Ph.D, Myron S. Czuczman, MD, Francisco Hernandez, MD

Blood (2013) 122 (21): 1836.

https://doi.org/10.1182/blood.V122.21.1836.1836

Published: 2013

Journal Articles

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

Magdalena Klanova, Lucie Lorkova, MSc, Ondrej Vit, MSc, Bokang Maswabi, MD, Jan Molinsky, MD, Jana Pospisilova, MSc, Cory Mavis, BSc, MSc, Francisco Hernandez, MD, Martin Vokurka, MD, PhD, Jiri Petrak, MSc, PhD, Pavel Klener, Jr., MD, PhD

Blood (2013) 122 (21): 3835.

https://doi.org/10.1182/blood.V122.21.3835.3835

Published: 2013

NARROW

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Selectively Targeting Checkpoint Kinase By Prexasertib Had Potent Anti-Tumor Activity As Single Agent or Combined with Other Chemotherapeutic Drugs in Diffuse Large B-Cell Lymphoma, Especially Double Hit Lymphoma

GSK458 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in T Cell Lymphomas As a Single Agent and in Combination Therapy

Targeting XIAP Via Degradation of MDM-2 By MX69 in Aggressive Lymphomas

Omipalisib (GSK458), a Dual an-PI3K/mTOR Inhibitor, Exhibits in Vitro and In Vivo activity in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Effects of Proteasome Inhibition in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models

Repurposing Itraconazole As an Anti-Cancer Agent Against Diffuse Large B-Cell Lymphoma

Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma

XIAP Knockdown Can Increase the Activity of Caspase 3 and 7, and Restore the Apoptotic Response in Cell Line Models of Rituximab Relapse/Refractory B-Cell Lymphoma

Targeting Mcl-1 By Proteasome Inhibitors Enhances the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-Clinical Models

Pre-Clinical Development of Targeted Therapies for Double Hit (DH) Diffuse Large B-Cell Lymphoma (DLBCL)

PI3K/Akt/mTOR Pathway Inhibition in Chemotherapy-Sensitive and -Resistant Models of Burkitt Lymphoma

Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemoresponsiveness in Burkitt Lymphoma Pre-Clinical Models

MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo

MLN4924 An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE) Is Active In Pre-Clinical Models Of Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma

Altered Glucose Metabolism In Rituximab-Chemotherapy Resistant Cells Is a Potential Target For Future Therapeutic Development

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Ixazomib, An Investigational Orally Bioavailable Proteasome Inhibitor, Increases p21 Expression Inducing Caspase-Dependent Cell Death, Cell-Cycle Arrest, and In B-Cell Lymphoma Pre-Clinical Models

CBL-C137, a Curaxin and Potent Suppressor Of NF-Kb Activity and Modulator Of p53 Function Is Active In Rituximab-Sensitive Or Resistant Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Downregulation Of Deoxycytidine Kinase In Cytarabine-Resistant Mantle Cell Lymphoma Cells Confers Cross-Resistance To Nucleoside Analogs Fludarabine, Gemcitabine and Cladribine, But Not To Other Classes Of Anti-Lymphoma Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only